Cue Biopharma, Inc. Operating Lease Liability
Cue Biopharma, Inc. (CUE) had Operating Lease Liability of $3.08 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Liabilities
us-gaap:OperatingLeaseLiability · last filed 2026-08-14
- 2026-06-30: Operating Lease, Liability $3.08M.
- 2026-03-31: Operating Lease, Liability $3.44M.
- 2025-12-31: Operating Lease, Liability $4.20M.
- 2025-09-30: Operating Lease, Liability $4.71M.
| Period end | Operating Lease, Liability |
|---|---|
| 2026-06-30 | $3.08M 10-Q · filed 2026-08-14 |
| 2026-03-31 | $3.44M 10-Q · filed 2026-05-14 |
| 2025-12-31 | $4.20M 10-K · filed 2026-03-16 |
| 2025-09-30 | $4.71M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $5.22M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $3.75M 10-Q · filed 2025-05-12 |
| 2024-12-31 | $4.54M 10-K · filed 2025-03-31 |
| 2024-09-30 | $4.22M 10-Q · filed 2024-11-14 |
| 2024-06-30 | $5.01M 10-Q · filed 2024-08-14 |
| 2024-03-31 | $5.79M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $6.53K 10-K · filed 2024-03-28 |
| 2023-09-30 | $7.25M 10-Q · filed 2023-11-03 |
| 2023-06-30 | $7.96M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $8.66M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $9.32M 10-K · filed 2023-03-21 |
| 2022-09-30 | $9.77M 10-Q · filed 2022-11-14 |
| 2022-06-30 | $9.95M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $10.15M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $10.05M 10-K · filed 2022-03-16 |
| 2021-09-30 | $3.63M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $4.87M 10-Q · filed 2021-08-09 |
| 2021-03-31 | $6.07M 10-Q · filed 2021-05-10 |
| 2020-12-31 | $7.15M 10-K · filed 2021-03-09 |
| 2020-09-30 | $8.20M 10-Q · filed 2020-11-09 |
| 2020-06-30 | $8.43M 10-Q · filed 2020-08-07 |
| 2020-03-31 | $4.71M 10-Q · filed 2020-05-07 |
| 2019-12-31 | $5.80M 10-K · filed 2020-03-12 |
| 2019-09-30 | $7.04M 10-Q · filed 2019-11-07 |
| 2019-06-30 | $7.82M 10-Q · filed 2019-08-08 |
| 2019-03-31 | $8.59M 10-Q · filed 2019-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |